In this Section |
153927 Cost savings from the provision of specific methods of contraceptionMonday, November 5, 2007
Introduction: Although research has shown substantial savings in public expenditures from subsidizing family planning services to low-income women, there is little information on the relative cost-effectiveness of specific contraceptive methods. The literature shows the theoretical cost effectiveness of different methods of contraception, not taking into account the likelihood of method discontinuation. In this study we examine cost savings from specific methods of contraception by assessing the cost of visits and pregnancies that may occur by method type.
Methods: We compare the costs of providing contraceptives through the large California State Family PACT program to the costs of unintended pregnancy to public programs using contraceptive method dispensing data for 955,000 women in 2003. We estimate the number of pregnancies averted through use of specific contraceptive methods to be the difference between Family PACT client pregnancies and the number of pregnancies expected in the absence of that method given the previous method dispensed. Results: Among short-term methods, the injectable contraceptives have the highest savings at $5.46 saved per dollar in services, followed by oral contraceptives ($4.28), the patch ($3.12), and the ring ($2.56). Barrier methods and emergency contraception have lower savings at approximately $1.50 per dollar spent on services. Expenditures on services for adolescents yield approximately twice the savings as services for adults. Discussion: Expenditures on all contraceptive methods have a positive return in preventing unintended pregnancy. Policy makers may use these findings for justifying coverage of all contraceptive methods. Potential contraceptive users may use the findings to assist in method selection.
Learning Objectives: Keywords: Contraceptives, Economic Analysis
Presenting author's disclosure statement:
Any relevant financial relationships? No I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Issues in Contraceptive Technology
See more of: Population, Family Planning, and Reproductive Health |